8:00 am Coffee & Registration

9:15 am Chair’s Opening Remarks

Target Selection & Validation

9:30 am Expanding TCR Therapy by Identifying New Targets and TCRs from Patient TILs

• Gavin MacBeath Chief Scientific Officer, TScan Therapeutics

10:00 am Functional Optimization and Characterization of TCRs Using Engineered Cell-Based Tools

• Hugh Salter Chief Scentific Officer, Anocca AB

10:30 am Morning Refreshments & Networking

11:30 am Identification of Novel Shared Targets in Solid Tumors

• Hans-Peter Gerber Chief Scientific Officer, 3T Biosciences

12:00 pm Developing Novel Tools for Selection and Prediction of Targets for Immunotherapy and Beyond

• Anthony Purcell Professor Biochemistry & Molecular Biology, Monash Biomedicine Discovery Institute

12:30 pm Revealing a Humanized TCR Mouse Platform for High Affinity TCR Discovery

• Elisa Kieback CEO, T-knife

1:00 pm Lunch & Networking

Next-Generation TCR-T Development

2:00 pm Opportunities in Solid Tumors

• Paul Lammers Chief Executive Officer, Triumvira

2:30 pm Next-Generation Genetic Modification of T-Cells Using Non-Viral Therapy

• Laurence Cooper Chief Executive Officer, Ziopharm Oncology

3:00 pm Afternoon Refreshments & Networking

Future Directions for TCR-T Products

4:00 pm Creating the Perfect Vehicle for TCRs from engineered iPSCs

• Bob Valamehr Chief Development Officer, Fate Therapeutics

4:30 pm Panel Discussion & Mastermind Session: Planning Ahead: A Commercial Future for Safe & Efficacious TCR-based Therapy Products

• Chia Chen-Rogers Senior Director, Oncology Cell Therapy New Products, GSK

5:00 pm Chair’s closing remarks

5:15 pm Close of Summit